2022
Development of an immunohistochemical assay for Siglec-15
Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Development of an immunohistochemical assay for Siglec-15. Laboratory Investigation 2022, 102: 771-778. PMID: 35459795, PMCID: PMC9253057, DOI: 10.1038/s41374-022-00785-9.Peer-Reviewed Original ResearchConceptsSiglec-15IHC assaysPD-L1PD-1/PD-L1 inhibitionPD-L1 blockadePD-L1 inhibitionHigh expressionFuture clinical trialsImmunoglobulin-type lectinsSiglec-15 expressionCompanion diagnostic assayPromising new targetTumor histologyImmunotherapeutic targetLung cancerImmune cellsClinical trialsNovel recombinant antibodiesCancer histologyImmunohistochemical assaysMyeloid cellsTumor typesScoring systemNew targetsHigh concordancePredictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.Peer-Reviewed Original ResearchConceptsBasal-like triple-negative breast cancerPathologic complete responseResidual diseaseNeoadjuvant durvalumabDNA damage repairSomatic mutationsBreast cancerWnt/β-cateninHigh expressionTriple-negative breast cancerBasal-Like TripleDoxorubicin/cyclophosphamideDNA repairTumor mutation burdenRNA sequencingEpithelial-mesenchymal transitionFive-gene signatureB-cell markersCancer driversEnrichment analysisNegative breast cancerDamage repairGene expressionJAK-STATCell cycle
2018
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. Breast Cancer Research 2018, 20: 154. PMID: 30558648, PMCID: PMC6298021, DOI: 10.1186/s13058-018-1076-x.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, CDAntigens, Differentiation, MyelomonocyticAntineoplastic AgentsBiomarkers, TumorBreastBreast NeoplasmsDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMacrophagesMatrix Metalloproteinase 9Middle AgedPatient SelectionPrognosisReceptors, Cell SurfaceReceptors, EstrogenRetrospective StudiesSurvival AnalysisTissue Array AnalysisTumor MicroenvironmentConceptsTumor-associated macrophagesOverall survivalQuantitative immunofluorescenceMacrophage markersBreast cancerHigh expressionPan-macrophage marker CD68Triple-negative breast cancerCD163/CD68Multiplexed quantitative immunofluorescenceImproved overall survivalProtein expressionWorse overall survivalPoor overall survivalMMP-9 protein expressionSubclass of patientsMacrophage-targeted therapiesMatrix metalloproteinase-9Tissue microarray formatMMP-9 proteinBreast tumor microenvironmentModulator of responseParaffin-embedded tissuesBreast cancer biomarkersCohort B
2011
Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Research 2011, 13: r85. PMID: 21888627, PMCID: PMC3262195, DOI: 10.1186/bcr2937.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCohort StudiesCyclophosphamideCytoplasmDocetaxelDoxorubicinEpithelial CellsFemaleFluorouracilHumansKaplan-Meier EstimateMiddle AgedPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRetrospective StudiesSurvival RateTau ProteinsTaxoidsConceptsOverall survivalBreast cancer cohortTreatment armsPredictive markerCancer cohortPredictive valueResponse rateConventional whole tissue sectionsMAP-tauImproved overall survivalHigh expressionMicrotubule associated protein tauTaxane-based chemotherapyKaplan-Meier analysisLonger median timeUseful predictive markerCox univariate analysisIndependent breast cancer cohortsWhole tissue sectionsFAC chemotherapyLonger TTPMedian timeMeier analysisPrognostic valueClinicopathologic variables
2008
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression
Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, Liu J, Khramtsov A, Tretiakova MS, Krausz TN, Olopade OI, Rimm DL, White KP. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Molecular Systems Biology 2008, 4: msb200825. PMID: 18414489, PMCID: PMC2394496, DOI: 10.1038/msb.2008.25.Peer-Reviewed Original ResearchConceptsHistone variant H2A.ZVariant H2A.ZBreast cancer progressionTranscription factor-binding sitesTranscriptional regulatory cascadeCancer progressionGenome tiling arraysWhole-genome mappingFactor-binding sitesRegulatory cascadeTiling arraysChromatin immunoprecipitationGenome mappingGenomic analysisH2A.Z levelsRNA interferenceGene targetsGene expressionEpigenetic factorsMicroarray screeningH2A.ZCell proliferationLymph node metastasisBreast cancer survivalHigh expression
2007
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. Journal Of Translational Medicine 2007, 5: 6. PMID: 17257402, PMCID: PMC1796544, DOI: 10.1186/1479-5876-5-6.Peer-Reviewed Original ResearchConceptsMetastatic melanomaXIAP expressionCell linesCy5-conjugated antibodiesMechanism of actionMelanoma cell linesPrimary lesionOvarian cancerTherapeutic approachesTissue microarrayDisease aggressionCarboplatin sensitivityChemotherapy resistanceMalignant progressionClinical specimensBenign counterpartsCarboplatinMelanomaChemotherapy sensitizationPrimary specimensPhenoxodiolResistant cellsMelanoma cellsHigh expressionMelanoma resistance
2006
Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma
Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006, 25: 6959-6967. PMID: 16715134, DOI: 10.1038/sj.onc.1209682.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCadherinsCell Line, TumorColonic NeoplasmsEnzyme ActivationEpithelial CellsHumansImmunohistochemistryImmunoprecipitationNeoplasm InvasivenessPrognosisPromoter Regions, GeneticProto-Oncogene Protein c-ets-1Reverse Transcriptase Polymerase Chain ReactionRho GTP-Binding ProteinsRhoA GTP-Binding ProteinRhoC GTP-Binding ProteinRNA, Small InterferingTranscription, GeneticConceptsColon carcinomaRhoC expressionPrognostic markerRhoC protein expressionE-cadherinET-1 binding sitesClinical outcomesPoor outcomeColon cancer cellsColorectal tumorsET-1Colon cancerUse of shRNAMesenchymal transitionExpression correlatesCarcinomaAberrant expressionHigh expressionProtein expressionCancer cellsMesenchymal characteristicsEMTSubsequent activationReciprocal regulationCell migration
2005
Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal Of The National Cancer Institute 2005, 97: 1808-1815. PMID: 16368942, DOI: 10.1093/jnci/dji427.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, NeoplasmBiomarkers, TumorCell Line, TumorConfidence IntervalsEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedNeoplasmsOdds RatioPredictive Value of TestsPrognosisProtein Array AnalysisReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsDisease-specific mortalityHigh HER2 expressionHER2 expressionAntibody concentrationsHigh expressionPoor survivalRelative riskTissue microarrayCumulative disease-specific survivalBiomarker expressionLong-term survival dataLow expressionHER2 antibodyX-tile programDisease-specific survivalLow HER2 expressionKaplan-Meier methodBreast cancer patientsExpression of HER2Higher antibody concentrationsLow antibody concentrationsConcentration of antibodyCancer patientsPatient outcomesSitu protein expressionCoexpression of β1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome
Siddiqui SF, Pawelek J, Handerson T, Lin CY, Dickson RB, Rimm DL, Camp RL. Coexpression of β1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome. Cancer Epidemiology Biomarkers & Prevention 2005, 14: 2517-2523. PMID: 16284372, DOI: 10.1158/1055-9965.epi-05-0464.Peer-Reviewed Original ResearchConceptsSubstrate proteinsEpidermal growth factor receptorGrowth factor receptorLAMP-1Glycoprotein substratesFactor receptorComplex oligosaccharide side chainsN-cadherin expressionTumor progressionOligosaccharide side chainsBeta1 integrin expressionGnT-VN-cadherinUnsupervised hierarchical clusteringN-acetylglucosaminyltransferaseMatriptaseDistinct clustersProteinProtein expressionTumor metastasisExpressionHigh expressionAggressive breast cancerLow expressionSide chains